| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
On Monday, Cathie Wood-led Ark Invest made a series of trades, with a significant purchase of shares in Block Inc (NYSE:SQ) standing out.
The Block Trade
Ark Invest's acquisition of 18,574 shares of Block underscores Wood's confidence in the company led by Jack Dorsey. The trade, valued at $811,869, was made through ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW). Block shares closed at $43.71 on Monday.
Despite facing challenges, including a controversial report by Hindenburg Research, Wood remains bullish on Block's prospects. The purchase is seen as a reaffirmation of Ark's stance, emphasizing the fund's long-term investment strategy and belief in Block's innovative approach to financial services.
See Also: Ark Israel Innovative Tech ETF Braces for Impact Amid Regional Warfare
Archer Aviation and CRISPR Therapeutics
Alongside the Block acquisition, Ark Invest also bolstered its position in Archer Aviation (NYSE:ACHR) and CRISPR Therapeutics AG (NASDAQ:CRSP). The fund management company purchased 163,809 Archer shares through ARKK and ARK Autonomous Technology & Robotics ETF (BATS:ARKQ). and 113,772 CRISPR shares on Monday through ARKK, and ARK Genomic Revolution ETF (BATS:ARKG). The transactions were estimated to be worth $846,892 and $4.8 million respectively. Archer shares closed at $5.17 on Monday, while CRISPR shares ended that day’s session at $42.51.
The fund's bullish stance on flying cars is evident with the purchase of 139,858 shares of Archer Aviation, a company at the forefront of the urban air mobility revolution.
The investment in 81,413 shares of CRISPR Therapeutics, a leader in the genome editing space, aligns with Ark's focus on innovative companies. CRISPR's groundbreaking technologies hold the promise of revolutionizing medicine, making it a significant addition to Ark's portfolio.
Other Key Trades:
Read Next: Is Cathie Wood the Next Warren Buffett? Apple, Tesla Define Their Investment Strategies
Engineered by Benzinga Neuro, Edited by Shivdeep Dhaliwal
The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
Posted In: ACHR ARKG ARKK ARKQ ARKW ARKX CRSP DNA MKFG PACB SQ
